ImmunityBio Responds to FDA Warning Letter, Clarifies Ad Never Aired

summarizeSummary

ImmunityBio has submitted a comprehensive response to the FDA's warning letter regarding promotional materials, confirming the cited television advertisement was never broadcast and outlining corrective actions.

check_boxKey Events

• FDA Warning Letter Response Submitted

  ImmunityBio submitted a comprehensive response to the U.S. FDA Office of Prescription Drug Promotion (OPDP) regarding a warning letter issued on March 13, 2026.

• TV Advertisement Never Aired

  The company confirmed that the television advertisement cited in the FDA's warning letter was never broadcast, aired, or disseminated to the public.

• Corrective Actions Implemented

  ImmunityBio has removed the identified podcast from its corporate website and is implementing enhanced advertising compliance measures, including expanded review protocols and executive training.

• Commitment to Compliance

  The company reaffirmed its dedication to ensuring all promotional communications for ANKTIVA® are accurate, balanced, and compliant with FDA regulations.

auto_awesomeAnalysis

This 8-K provides a crucial update to the FDA warning letter reported on March 24, 2026. ImmunityBio's comprehensive response, including the immediate removal of the identified podcast and the clarification that the television advertisement cited was never aired, significantly mitigates the potential impact of the initial regulatory concern. The company's commitment to enhanced compliance protocols and executive training demonstrates a proactive approach to addressing the FDA's feedback, which should reassure investors regarding future promotional activities for ANKTIVA.